$3.25
34.87%
Nasdaq, Fri, Sep 25 2026.
ISIN
US04746L1044
Symbol
ATHA

Athira Pharma Inc Stock price

$3.25
-4.76 59.43% 1M
-5.78 64.01% 6M
-4.32 57.07% YTD
-0.56 14.70% 1Y
-16.55 83.59% 3Y
-95.05 96.69% 5Y
-166.75 98.09% 10Y
-166.75 98.09% 20Y
Nasdaq, Closing price Fri, Sep 25 2026
-1.74 34.87%
ISIN
US04746L1044
Symbol
ATHA
Industry

Is Athira Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$25.2m
Shares outstanding
3.9m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
76.3%
Return on Equity
-216.2%
ROCE
-144.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-38.3m
EBIT
$-39.3m
Net Income
$-37.7m
Free Cash Flow
$-52.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
65.5%
EBIT
64.9%
Net Income
65.5%
Free Cash Flow
46.3%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-9.6
FCF per Share
$-13.3
Short interest
0.2%
Employees
26
Rev per Employee
$0.0

Athira Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Athira Pharma Inc forecast:

4x Hold
57%
3x Sell
43%

Analyst Opinions

7 Analysts have issued a Athira Pharma Inc forecast:

Hold
57%
Sell
43%

Financial data from Athira Pharma Inc

Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
29% 29%
-
- Research and Development Expense 20 20
76% 76%
-
-38 -38
65% 65%
-
- Depreciation and Amortization 0.97 0.97
1% 1%
-
EBIT (Operating Income) EBIT -39 -39
65% 65%
-
Net Profit -38 -38
65% 65%
-

In millions USD.

Don't miss a Thing! We will send you all news about Athira Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company was founded by Leen Kawas and Joseph Harding in 2011 and is headquartered in Seattle, WA.

Head office United States
CEO Dr. Litton
Employees 26
Founded 2011
Website www.athira.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today